GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $64.82 $75.66 Friday, 19th Apr 2024 CYTK stock ended at $67.55. This is 0.82% more than the trading day before Thursday, 18th Apr 2024. During the day the stock fluctuated 4.60% from a day low at $64.82 to a day high of $67.80.
90 days $61.33 $84.92
52 weeks $25.98 $110.00

Historical Cytokinetics prices

Date Open High Low Close Volume
2024-02-07 $80.23 $80.40 $77.00 $77.12 1 423 975
2024-02-06 $80.27 $80.79 $78.05 $80.16 949 922
2024-02-05 $79.23 $80.66 $76.56 $80.16 2 607 478
2024-02-02 $80.49 $84.05 $79.29 $81.87 2 281 350
2024-02-01 $78.52 $82.64 $78.49 $81.25 2 369 451
2024-01-31 $78.73 $81.41 $77.69 $78.13 1 814 114
2024-01-30 $79.96 $80.44 $77.28 $78.73 2 153 300
2024-01-29 $81.67 $81.89 $79.56 $79.99 2 332 384
2024-01-26 $84.00 $84.00 $80.65 $82.74 1 160 242
2024-01-25 $82.94 $83.73 $80.55 $82.91 1 725 916
2024-01-24 $83.42 $84.11 $81.50 $81.77 1 663 119
2024-01-23 $83.69 $84.92 $80.86 $84.80 1 388 884
2024-01-22 $81.20 $84.08 $80.56 $83.69 2 053 821
2024-01-19 $82.68 $83.73 $80.02 $80.96 3 377 053
2024-01-18 $84.97 $86.63 $81.59 $82.74 2 530 651
2024-01-17 $80.93 $86.19 $80.13 $85.68 3 365 456
2024-01-16 $82.50 $85.05 $80.22 $81.19 4 027 596
2024-01-12 $85.51 $86.98 $83.86 $85.60 4 874 039
2024-01-11 $99.97 $100.49 $73.12 $84.95 23 934 270
2024-01-10 $100.00 $103.75 $97.74 $101.63 7 161 165
2024-01-09 $108.55 $108.61 $95.51 $101.97 11 735 620
2024-01-08 $89.30 $110.00 $85.86 $108.06 14 849 599
2024-01-05 $87.24 $95.49 $86.82 $93.73 6 002 564
2024-01-04 $87.00 $90.20 $85.80 $88.24 5 534 129
2024-01-03 $83.49 $87.76 $82.15 $86.64 3 977 978
Click to get the best stock tips daily for free!

About Cytokinetics

Cytokinetics Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in pati... CYTK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT